The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
39 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,881,503 in first-year total cost, median $394,375.
Most frequent study sections
- Neurological Sciences and Disorders C Study Section[NSD-C]14
- Neurological Sciences and Disorders A Study Section[NSD-A]13
- Neurological Sciences and Disorders B Study Section[NSD-B]12
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL2
- CASE WESTERN RESERVE UNIVERSITY2
- MASSACHUSETTS GENERAL HOSPITAL2
- RESEARCH INST NATIONWIDE CHILDREN'S HOSP2
- UNIV OF NORTH CAROLINA CHAPEL HILL2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Small-Molecule Pharmacological Chaperones to Prevent Synuclein Transmission1R21NS092897-01 | MCCONLOGUE, LISA C | J. DAVID GLADSTONE INSTITUTES, CA | $473,250 | NSD |
| 2015 | Optimization of a novel series of thiazolopyridines for the treatment of SMA1R21NS088522-01A1 | ANDROPHY, ELLIOT J.HODGETTS, KEVINLORSON, CHRISTIAN L. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $447,563 | NSD |
| 2015 | Translation of AAV P0 ICE schwannoma gene therapy to clinical Trials1R21NS088013-01A1 | BRENNER, GARY JAY | MASSACHUSETTS GENERAL HOSPITAL, MA | $430,984 | NSD |
| 2015 | Chimeric Anti-Fibulin-3 Reagents For Targeted Therapy Of Glioblastoma1R21NS091436-01 | VIAPIANO, MARIANO SEBASTIAN | BRIGHAM AND WOMEN'S HOSPITAL, MA | $423,853 | NSD |
| 2015 | Adenosine kinase antisense gene therapy for temporal lobe epilepsy.1R21NS088024-01A1 | BOISON, DETLEV | LEGACY EMANUEL HOSPITAL AND HEALTH CENTER, OR | $412,500 | NSD |
| 2015 | Nanoformulation of the BDNF for treatment of stroke1R21NS088152-01A1 | KABANOV, ALEXANDER V | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $411,216 | NSD |
| 2015 | A Pharmaco-Epigenomic Intervention for the Mitochondrial Disorder MELAS1R21NS085282-01A1 | CHIARAMELLO, ANNE ELIANE | GEORGE WASHINGTON UNIVERSITY, DC | $408,354 | NSD |
| 2015 | Xenon As A Therapeutic in Experimental Intracerebral Hemorrhage1R21NS087157-01A1 | WARNER, DAVID | DUKE UNIVERSITY, NC | $396,250 | NSD |
| 2015 | Remote ischemic conditioning for neuroprotection in vascular cognitive impairment1R21NS090609-01A1 | HESS, DAVID C. | AUGUSTA UNIVERSITY, GA | $380,000 | NSD |
| 2015 | Targeting the Chaperone Pathway for Myelin Repair in Hereditary Neuropathies1R21NS091435-01 | NOTTERPEK, LUCIA | UNIVERSITY OF FLORIDA, FL | $375,000 | NSD |
| 2015 | An Agonist Antibody to MuSK As A Theraputic For MuSK Myasthenia Gravis1R21NS088723-01A1 | BURDEN, STEVENVAN DER MAAREL, SILVERE M | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $364,250 | NSD |
| 2015 | Examination of a novel therapy to induce voiding after spinal cord injury1R21NS089880-01A1 | MARSON, LESLEY | DIGNIFY THERAPEUTICS, LLC, NC | $350,000 | NSD |
| 2014 | Transcription therapeutics for myotonic dystrophy type 11R21NS086980-01A1 | DERVAN, PETER BGOTTESFELD, JOEL M.THORNTON, CHARLES A | SCRIPPS RESEARCH INSTITUTE, THE, CA | $480,950 | NSD |
| 2014 | TAAR1 agonists as wake-promoting and cognitive-enhancing therapeutics1R21NS085757-01A1 | KILDUFF, THOMAS SWALLACE, TANYA L | SRI INTERNATIONAL, CA | $476,989 | NSD |
| 2014 | Identification of therapeutic compounds for Charcot-Marie-Tooth disease type 1E/11R21NS087194-01 | PATEL, PRAGNA | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $443,738 | NSD |
| 2014 | Development of novel JAK/STAT inhibitors for Epilepsy prevention and treatment1R21NS083057-01A1 | BROOKS-KAYAL, AMY R.RUSSEK, SHELLEY J | UNIVERSITY OF COLORADO DENVER, CO | $426,074 | NSD |
| 2014 | IL13Ra2 targeted T-cell therapy for glioma1R21NS089802-01 | BALYASNIKOVA, IRINA VGOTTSCHALK, STEPHEN | UNIVERSITY OF CHICAGO, IL | $408,625 | NSD |
| 2014 | Using Patient-Derived Neurons for Epilepsy Drug Discovery1R21NS087181-01 | CRINO, PETER B | TEMPLE UNIV OF THE COMMONWEALTH, PA | $402,806 | NSD |
| 2014 | Immunomodulatory effects of Inter-alpha Inhibitors in attenuating Ischemic Stroke1R21NS087183-01A1 | MCCULLOUGH, LOUISE D. | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $401,028 | NSD |
| 2014 | Dictyostatin and related prodrugs as candidates for tauopathy treatment1R21NS087059-01A1 | SMITH, AMOS B | UNIVERSITY OF PENNSYLVANIA, PA | $400,000 | NSD |
| 2014 | High throughput screening and in vivo testing of drugs to enhance remyelination1R21NS085246-01 | MILLER, ROBERT H.TESAR, PAUL JOSEPH | CASE WESTERN RESERVE UNIVERSITY, OH | $396,250 | NSD |
| 2014 | Preclinical evaluation of NMDA receptor antagonists for treating Rett Syndrome1R21NS087132-01A1 | KATZ, DAVID M. | CASE WESTERN RESERVE UNIVERSITY, OH | $396,250 | NSD |
| 2014 | Novel adoptive transfer therapy for glioma using CAR-transduced Type17 T-cells1R21NS083171-01A1 | OKADA, HIDEHO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $395,208 | NSD |
| 2014 | Soluble VEGF receptor therapy for brain arteriovenous malformation1R21NS083788-01A1 | SU, HUA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $394,375 | NSD |
| 2014 | Novel Combinatorial Therapies for Malignant Peripheral Nerve Sheath Tumors1R21NS084885-01A1 | CRIPE, TIMOTHY PRATNER, NANCY | CINCINNATI CHILDRENS HOSP MED CTR, OH | $393,455 | NSD |
| 2014 | LM11A-31 neuroprotective efficacy in an animal model of HIV1R21NS086426-01A1 | MEEKER, RICK B | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $391,967 | NSD |
| 2014 | Antisense oligonucleotides to treat spinal and bulbar muscular atrophy1R21NS089516-01 | LIEBERMAN, ANDREW P | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $388,542 | NSD |
| 2014 | Evaluating a novel pathway for treatment of Duchenne muscular dystrophy1R21NS088691-01 | FROEHNER, STANLEY CWHITEHEAD, NICHOLAS | UNIVERSITY OF WASHINGTON, WA | $386,250 | NSD |
| 2014 | A Novel Xenograft Model of FSHD1R21NS086902-01A1 | BLOCH, ROBERT J | UNIVERSITY OF MARYLAND BALTIMORE, MD | $383,750 | NSD |
| 2014 | Creation and correction of Spinal Muscular Atrophy in the pig1R21NS083804-01A1 | BURGHES, ARTHUR H. M.KASPAR, BRIAN K. | OHIO STATE UNIVERSITY, OH | $379,525 | NSD |
| 2014 | Therapeutic targeting of aberrant glial function during Juvenile Batten Disease1R21NS084392-01A1 | KIELIAN, TAMMY L | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $376,250 | NSD |
| 2014 | New Nonsense Suppression Drugs to Treat MPS I1R21NS090928-01 | BEDWELL, DAVID M.KEELING, KIM MARIE | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $367,500 | NSD |
| 2014 | Directing Splicing of SCN8A to Treat Dravet Syndrome1R21NS087162-01A1 | TALLENT, MELANIE K | LIFESPLICE PHARMA, LLC, PA | $342,600 | NSD |
| 2014 | Angiotensin receptor agonism to promote recovery after stroke1R21NS088016-01 | FAGAN, SUSAN C | UNIVERSITY OF GEORGIA, GA | $325,500 | NSD |
| 2014 | Small chemical modulators of SMN biology as candidate therapeutics for SMA1R21NS083831-01A1 | PELLIZZONI, LIVIO | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $320,000 | NSD |
| 2014 | Novel 12/15 lipoxygenase inhibitors for the treatment of stroke1R21NS087165-01 | VAN LEYEN, KLAUS | MASSACHUSETTS GENERAL HOSPITAL, MA | $302,648 | NSD |
| 2014 | Deep brain stimulation to prevent impaired consciousness in epilepsy1R21NS083783-01A1 | BLUMENFELD, HAL | YALE UNIVERSITY, CT | $249,750 | NSD |
| 2014 | Dual-vector mediated mini-dystrophin restoration of function in mdx model of DMD1R21NS085265-01A1 | MENDELL, JERRY ROY | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $219,750 | NSD |
| 2014 | Lentivirus Transduced Tolerogenic Dendritic Cells For The Treatment Of CIDP1R21NS085278-01A1 | SAHENK, ZARIFE | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $158,503 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.